Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 7/3/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Zvi Ram?

Zvi Ram

Neurosurgeon, Head of Neurosurgery Department

The Tel Aviv Sourasky Medical Center

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

The Tel Aviv Sourasky Medical Center

Background Information

Employment History

Chairman of the Department of Neurosurgery

TAM


Affiliations

Brain Tumor Biotech Center

Medical Advisory Board Member


ImmunoCellular Therapeutics, Ltd.

Scientific Advisory Board Member


AANS/CNS

Member of the Executive Committee of the Section


Education

M.D.


Web References(25 Total References)


Israeli doctors | MedPlus Ltd

medplus-israel.com [cached]

Prof. Zvi Ram
Prof. Zvi Ram Neurosurgeon, head of Neurosurgery Department at The Tel Aviv Sourasky Medical Center . Graduated Sackler School of Medicine, today Dr. Ram is present professor of surgery (neurosurgery), that has an extensive practical experience recognized by several awards.


Israeli doctors | MedPlus Ltd

medplus-israel.com [cached]

Prof. Zvi Ram
Prof. Zvi Ram Neurosurgeon, head of Neurosurgery Department at The Tel Aviv Sourasky Medical Center . Graduated Sackler School of Medicine, today Dr. Ram is present professor of surgery (neurosurgery), that has an extensive practical experience recognized by several awards.


Novocure Announces Agenda for Research and Development Day on Dec. 12, 2016 | Business Wire

www.businesswire.com [cached]

Zvi Ram, MD, Director of Neurosurgery at the Tel-Aviv Sourasky Medical Center in Tel-Aviv
1:25 to 1:50 p.m.: TTFields and GBM, and the full, 695-patient dataset from Novocure's EF-14 trial in newly diagnosed GBM, Dr. Ram


Brain Tumor News: Electrical Device for Cancer Treatment Polarizes Audiences

virtualtrials.com [cached]

The device is also notable for the responses it elicits from professionals, according to Zvi Ram, MD, professor and chair of neurosurgery at Tel-Aviv Sourasky Medical Center in Israel.
To date, reports about the electrical device have elicited both antagonistic and enthusiastic reaction from oncologists, with "neither the enthusiasts nor the antagonists having significant bases for either kind of acute reaction," Dr. Ram told Medscape Medical News after his presentation. Dr. Ram did not dwell on the antagonism. "It's human nature," he said about such audience reactions. Traditional approaches to glioblastoma have a lot of room for improvement, explained Dr. Ram. Now, a post hoc analysis of several subgroups in the study has found some additional advantages, reported Dr. Ram. One subgroup of 110 "good prognosis" patients (younger than 60 years and with a Karnofsky Performance Scale score of more than 80) showed a "more robust" survival benefit than was seen in the overall intent-to-treat analysis, he said. In this subgroup, patients treated with NovoTTF had a median survival of 9.2 months, compared with 6.6 months for those treated with chemotherapy (P he explained. Moreover, 1-year overall survival in this subgroup was 35.2% with NovoTTF group, compared with 20.8% with chemotherapy (P Another subgroup analysis looked at patients who had previously failed treatment with bevacizumab (roughly 20% of the entire cohort). Both an intent-to-treat analysis and a per protocol analysis showed significant overall survival advantages for NovoTTF, said Dr. Ram. "You know these are going to be poor responders, almost identical to bevacizumab failure," said Dr. Ram. "We do this to all our patients; we intoxicate them," said Dr. Ram about the adverse effects of chemotherapy. "Even if NovoTTF did not extend survival, if it was equivalent to chemotherapy [for survival], then it may still improve quality of life." Dr. Ram did not know the median length of time that the NovoTTF cohort wore the device, but an earlier phase 2 study followed some of them for 59 months. "Seventy percent are still alive - that's unheard of," he remarked. "There were concerns that patients might have more headaches or seizures, but there were none," he said. Dr. Ram reported that the rate of adverse events related to the central nervous system (CNS) was similar for NovoTTF and chemotherapy (66% vs 67%), as were serious CNS adverse events (21% vs 22%), seizures (15% vs 12%), and headaches (18% vs 13%). "There are no real concerns that this does anything hazardous to the brain," he said. NSCLC Data Dr. Ram also presented evidence suggesting that NovoTTF therapy has benefits in other forms of cancer. A study reported by his colleagues earlier this year at the European Society for Medical Oncology Congress showed that NovoTTF therapy combined with chemotherapy resulted in significant prolongation of survival in patients with NSCLC, compared with historic controls, he said. "If this kind of therapy acts against brain cancer cells, it should act also against other tumor types," he reasoned. In the study, which looked at 42 NSLC patients, NovoTTF was delivered with newly designed electrodes placed on the chest and neck of patients with locally advanced metastatic stage IIIb and IV disease, he explained. Overall survival was better with the combination of NovoTTF plus pemetrexed than with pemetrexed alone (13.8 vs 8.3 months), as was the rate of 1-year survival rate (57% vs 30%). "We're talking about something that appears to be acting against cancer cells, regardless of origin," said Dr. Ram. Dr. Ram acknowledged that the per protocol analysis of the findings is unconventional, but that "there is no precedent for this kind of therapy. I think we may need to redesign the way we assess results in the future. We cannot use the same guidelines and definitions that we were traditionally using." Dr. Ram is a consultant for NovoCure, which sponsored the trial and manufactures the device.


www.eurekalert.org

Professor Zvi Ram presents phase III recurrent glioblastoma survival and quality of life data from the first pivotal study of the NovoTTF-100A at 15th Annual Society for Neuro-Oncology Scientific Meeting
Professor Zvi Ram presents phase III recurrent glioblastoma survival and quality of life data from the first pivotal study of the NovoTTF-100A at 15th Annual Society for Neuro-Oncology Scientific Meeting Professor Zvi Ram presents phase III recurrent glioblastoma survival and quality of life data from the first pivotal study of the NovoTTF-100A at 15th Annual Society for Neuro-Oncology Scientific Meeting MONTREAL, CANADA - November 19, 2010 - Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy. Professor Zvi Ram, chairman of the Department of Neurosurgery at Tel-Aviv Sourasky Medical Center, presented the data at the Society for Neuro-Oncology (SNO) Annual Scientific Meeting. "The study suggests that patients treated with TTF therapy, as defined in the protocol, lived significantly longer than patients treated with the currently available best chemotherapeutic regimens," said Professor Ram.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory